Description: Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Home Page: www.ergomedplc.com
Surrey Research Park
Guildford,
GU2 7HJ
United Kingdom
Phone:
44 1483 503 205
Officers
| Name | Title |
|---|---|
| Dr. Miroslav Reljanovic | Founder & Exec. Chairman |
| Mr. Richard T. Barfield | CFO & Exec. Director |
| Mr. Michael William Spiteri | Chief Transformation & Technology Officer |
| Mr. Shaun Hopgood | Chief Information Officer |
| Dr. Michael Forstner | Head of Risk Management & Pharmacoepidemiology |
| Ms. Sally Amanuel | Pres of PrimeVigilance |
| Dr. Gordana Tonkovic | Pres of Clinical Research |
| Ms. Ronel Steyn | Sr. VP of Global Devel. |
| Keith Byrne | Sr. Vice-Pres of Capital Markets & Strategy |
| Jonathan Curtain | Deputy CFO |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 26.3158 |
|---|---|
| Trailing PE: | 46.2759 |
| Price-to-Book MRQ: | 8.2764 |
| Price-to-Sales TTM: | 5.6343 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1371 |